Rinvoq and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported as a side effect among people who take Rinvoq (upadacitinib), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Entyvio, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Gastrointestinal inflammation when taking Rinvoq. It is created by eHealthMe based on reports of 47,330 people who have side effects when taking Rinvoq from the FDA, and is updated regularly.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. eHealthMe is studying from 47,375 Rinvoq users. Check the latest studies of Rinvoq.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 538 drugs and 548 conditions by eHealthMe. Check the latest studies of Gastrointestinal inflammation.

On Jul, 23, 2026

47,330 people reported to have side effects when taking Rinvoq.
Among them, 21 people (0.04%) have Gastrointestinal inflammation.

Could Rinvoq cause Gastrointestinal inflammation?

Among these 21 people:

How long have people been on Rinvoq when they have Gastrointestinal inflammation? *

What is the gender of people who have Gastrointestinal inflammation when taking Rinvoq? *

female: 40 %
male: 60 %

What is the age of people who have Gastrointestinal inflammation when taking Rinvoq? *

What are other drugs people take besides Rinvoq? *

What are other side effects people have besides Gastrointestinal inflammation? *

Diarrhea: 4 people, 19.05%
Abdominal Pain: 3 people, 14.29%
Weight Decreased: 2 people, 9.52%
Drug Ineffective: 2 people, 9.52%
Enteritis (inflammation of the small intestine): 2 people, 9.52%
Pain: 2 people, 9.52%
Rectal Haemorrhage (bleeding from anus): 2 people, 9.52%
Malaise (a feeling of general discomfort or uneasiness): 2 people, 9.52%
Anaemia (lack of blood): 2 people, 9.52%
Acne (skin problems that cause pimples): 2 people, 9.52%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 28.57%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 23.81%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 5 people, 23.81%
Pain: 2 people, 9.52%
Insomnia (sleeplessness): 1 person, 4.76%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 4.76%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 4.76%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 4.76%
Arrhythmias (irregular heartbeat): 1 person, 4.76%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Rinvoq and have Gastrointestinal inflammation?

- Check whether Gastrointestinal inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rinvoq:

Rinvoq (47,375 reports)

Browse all side effects of Rinvoq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (538 drugs)

Browse all the conditions that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (548 conditions)

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on upadacitinib (the active ingredients of Rinvoq) and Rinvoq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.